Brain Cancer And Cannabinoids
Glioma is one of the most aggressive malignant tumor forms, resistant to chemotherapy. 38 percent Glioblastoma endothelial cells are found in CB1 receptors and 54% in CB2. CB2 receptor expression is stronger in glioma tissues compared to CB1. Selective CB2 agonists are believed to have an effect on the treatment of this cancer. It has been shown that cannabinoids cause apoptosis of glioma tumor cells and disrupt tumor angiogenesis. It is also thought that cannabinoids that do not interact directly with either CB1 or CB2 receptors can modify Δ9-THC activity. Combination therapy with Δ9-THC and temozolomide (TMZ, antimicrobial therapy for gliomas) has a potent antitumour effect on glioma cells through activated autophagy processes. Sub-maximal Δ9-THC and CBD doses combined with TMZ have a potent antitumour effect on both TMZ susceptible and resistant forms. However, glioma cancer cells can also be resistant to cannabinoids during treatment. The method of microencapsulation (placement of the active substance in the capsule) can slow down the release of cannabinoids and increase their efficacy (Hernan Perez de la Ossa D et al., 2013).
Consult your doctor before using this diary supplement on your own responsibility.